Go back

Austria and Germany side with industry against EU pharma plans


Governments echo business complaints that Commission proposals could “hamper European science”

The governments of Austria and Germany have sided with drug companies in warning that proposed changes to EU pharmaceuticals laws could hinder medical R&D in Europe, even using almost identical language to voice their concerns.

In April, the European Commission proposed what it said would be “the largest reform in over 20 years” to EU pharma legislation. It wants medicines to be made available across the EU faster—including by reducing the time it takes for new medicines to win regulatory approval—and says the reforms will improve access to medicines and support innovation.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.